Expression studies of naturally occurring human dopamine transporter variants identifies a novel state of transporter inactivation associated with Val382Ala.

Mazei-Robison MS, Blakely RD
Neuropharmacology. 2005 49 (6): 737-49

PMID: 16212992 · DOI:10.1016/j.neuropharm.2005.08.012

Multiple, rare, human dopamine (DA) transporter (hDAT, SLC6A3) coding variants have been described, though to date they have been incompletely characterized. Here we present studies analyzing the function and regulation of five naturally occurring coding variants, V55A, R237Q, V382A, A559V and E602G, expressed in COS-7 and SH-SY5Y cells. All variants, except V382A, exhibited levels of surface protein expression and DA transport activity comparable to hDAT. V382A, divergent at the most highly conserved residue among reported hDAT variants, exhibited significantly diminished surface expression, likely derived from inefficient plasma membrane delivery. Moreover, a greater expression of V382A protein was required to achieve comparable levels of transport to hDAT, consistent with a loss of transport function. V382A displayed a decrease in sensitivity to phorbol ester (PMA)-induced internalization, as well as an altered substrate selectivity for DA versus norepinephrine (NE). Analysis of PMA-induced V382A internalization revealed a trafficking-independent action of PMA, consistent with the existence of a surface-localized, transport-inactive state.

MeSH Terms (29)

Alanine Amphetamine Animals Biotinylation Cattle Cell Line Chlorocebus aethiops Cocaine COS Cells Dopamine Dopamine Plasma Membrane Transport Proteins Dopamine Uptake Inhibitors Drug Interactions Electrophoresis, Polyacrylamide Gel Gene Expression Gene Expression Regulation Genetic Variation Humans Mice Models, Biological Mutagenesis Neuroblastoma Norepinephrine Phorbol Esters Protein Transport Rats Time Factors Transfection Valine

Connections (2)

This publication is referenced by other Labnodes entities: